GSK issues Seroxat warning letter
Antidepressant linked to increased risk of suicidal behaviour in young adults GlaxoSmithKline (GSK) has sent a letter to doctors warning them that there could be an elevated risk of suicidal behaviour in adults under 30 taking its antidepressant, Seroxat (sold as Paxil in the US). Having reanalysed data from clinical trials involving almost 15,000 people, the firm said there was a higher frequency of suicidal behaviour in young adults treated with the drug for depression than in those taking a placebo. The new analysis comes after the US Food and Drug Administration asked all manufacturers of anti-depression treatments to evaluate whether their products increased the risk of suicidal thoughts among adults. The FDA said its review of antidepressants is not yet complete and patients taking such drugs should be carefully monitored for worsening of depression and suicidal thinking. It also said it is essential that patients on Seroxat don't stop taking it suddenly. In a statement, GSK said that

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!